Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Using Glucose Sensors to Prevent Hypoglycemia

This study has been completed.
Information provided by (Responsible Party):
Edmond A Ryan, University of Alberta Identifier:
First received: November 2, 2007
Last updated: September 12, 2011
Last verified: September 2011

Hypoglycemia is the most common complication of Type 1 diabetes particularly in those who strive for good glycemic control. In some patients there is a loss of awareness of hypoglycaemia so that the first manifestation of hypoglycaemia may be confusion or coma. Such a situation may carry risks that the patient may harm him or her self. Medtronic has recently developed a continuous glucose sensor that determines the glucose level every 3 minutes using a subcutaneous sensor and transmits the information to a remote device (Paradigm RT) that may be worn or left close by eg on a bedside table. The device may be programmed to alarm for a rapidly falling glucose or for low glucose levels.

We propose to use this in 16 patients with severe hypoglycemia as evidenced by a high HYPO score and see if we can decrease the number of hypoglycemic reactions and document this improvement with a better HYPO score.

Condition Intervention Phase
Type 1 Diabetes
Device: Use of glucose sensor (Paradigm Guardian)
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Paradigm Real Time Continuous Glucose Monitoring Device for the Prevention of Hypoglycemia

Resource links provided by NLM:

Further study details as provided by University of Alberta:

Primary Outcome Measures:
  • Decrease in HYPO score [ Time Frame: 3 months ]

Secondary Outcome Measures:
  • Number of episodes of severe hypoglycemia [ Time Frame: 3 months ]
  • Number of patients who decide to continue using the device [ Time Frame: 3 months ]

Estimated Enrollment: 16
Study Start Date: October 2006
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: A
Run in period
Experimental: B Device: Use of glucose sensor (Paradigm Guardian)
Use glucose sensor to prevent episodes of severe hypoglycemia
Other Name: Paradigm Guardian glucose sensor

Detailed Description:

Sixteen patients with Type 1 diabetes (as defined by: onset under the age of 25, lean at time of onset, continuous insulin use, and/or history of ketoacidosis and C-peptide negative), with a HYPO score over the seventy-fifth percentile (>423), will be approached and offered the study.

The study will be conducted over a three month time-frame. The first month will be a run-in period for participants to collect four weeks of glucose readings and information about their hypoglycemic events. These records will be used to calculate the baseline modified HYPO score. Patients will be screened during the first month for thyroid disease, celiac disease and Addison's disease.

During the second month they will meet with the study nurse for an intensive instruction period on the use of the Paradigm RT sensor. They will spend this month practicing to use the sensor and confirming they can use it adequately.

During the final month they will wear the sensor and collect glucose and hypoglycemia records for calculation of the final modified HYPO score.

The end point will be the change from the baseline modified HYPO score to the final four week HYPO score and this would be used to identify any improvement.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 1 Diabetes Mellitus confirmed by C-peptide <0.10 nmol/L
  • age 18 - 70 yrs.
  • HYPO score >423
  • normal TSH, serum cortisol and anti-transglutaminase (ATTG)

Exclusion Criteria:

  • current diagnosis of cancer
  • planning a pregnancy
  • Inability to give informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00554281

Canada, Alberta
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2B7
University of Alberta
Edmonton, Alberta, Canada, T6G 2S2
Sponsors and Collaborators
University of Alberta
Principal Investigator: Edmond A Ryan, MD University of Alberta
  More Information

Responsible Party: Edmond A Ryan, Professor, University of Alberta Identifier: NCT00554281     History of Changes
Other Study ID Numbers: UAHREB6344
Study First Received: November 2, 2007
Last Updated: September 12, 2011

Keywords provided by University of Alberta:
Type 1 diabetes
Glucose sensor

Additional relevant MeSH terms:
Diabetes Mellitus, Type 1
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases processed this record on April 28, 2017